Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

101.90EUR
11:34am EST
Change (% chg)

€0.40 (+0.39%)
Prev Close
€101.50
Open
€101.40
Day's High
€102.30
Day's Low
€101.40
Volume
406,343
Avg. Vol
416,186
52-wk High
€103.95
52-wk Low
€71.15

Latest Key Developments (Source: Significant Developments)

Merck KGaA,Darmstadt, Germany, Pfizer and Syndax announces collaboration to evaluate combination of avelumab and entinostat in ovarian cancer
Monday, 4 Jan 2016 08:00am EST 

Merck KGaA:Says Co, Darmstadt, Germany, Pfizer and Syndax announces collaboration to evaluate combination of avelumab and entinostat in ovarian cancer.Says financial terms of the agreement were not disclosed.This is an exclusive agreement between the alliance and syndax to study the combination of two investigational agents in ovarian cancer.Says syndax will be responsible for conducting the phase ib/ii clinical trial in ovarian cancer.  Full Article

Merck KGaA acquires Ormet Circuits, no purchase price disclosed
Sunday, 13 Dec 2015 07:00pm EST 

Merck KGaA:Acquires Ormet Circuits, no purchase price disclosed.Says acquisition to enhance position as semiconductor materials supplier.Merck says deal complements existing integrated circuit materials business unit.  Full Article

Merck KGaA to invest extra 250 million euros in pharma pipeline
Wednesday, 9 Dec 2015 07:00pm EST 

Merck KGaA:Plans to invest extra 250 million euros in pharma pipeline.Sees one-off integration costs from sigma-aldrich of 400 million euros over 4 yrs.Expects cost savings of 90 million euros from sigma-aldrich takeover‍​.  Full Article

Merck KGaA, Threshold drug fails in late-stage cancer trials - Reuters
Sunday, 6 Dec 2015 10:11pm EST 

Merck KGaA:Merck KGaA MRCG.DE and development partner Threshold Pharmaceuticals THLD.O said their experimental cancer drug evofosfamide failed to extend lives in two late-stage clinical studies, a major setback for both firms - RTRS.Evofosfamide did not meet the main goal of improving survival in patients suffering from advanced pancreatic cancer and advanced soft tissue sarcoma, prompting the two companies to give up exploring the drug's use against these cancer forms. - RTRS.Merck said on Monday it would focus efforts on more promising candidates in its drug pipeline and would soon decide about evofosfamide's overall future - RTRS.The new disappointment leaves CEO-designate Stefan Oschmann, a pharmaceuticals expert, with a narrow drug development pipeline that rests mainly on cancer immune therapy avelumab, jointly developed with Pfizer - RTRS.  Full Article

Merck KGaA decides not to pursue evofosfamide further in soft tissue sarcoma and pancreatic cancer
Sunday, 6 Dec 2015 07:00pm EST 

Merck KGaA:Merck KGaA MRCG.DE and development partner Threshold Pharmaceuticals said their experimental cancer drug evofosfamide failed to show the desired effects in two late stage studies.Evofosfamide did not meet the main goal of improving overall survival in patients suffering from advanced pancreatic cancer and advanced soft tissue sarcoma, prompting the two companies to give up exploring the drug's use against the these cancer forms.  Full Article

Merck KGaA raises FY 2015 outlook
Wednesday, 11 Nov 2015 07:00pm EST 

Merck KGaA:Forecast for FY 2015 lifted thanks to good operational performance and Sigma-Aldrich acquisition.For FY 2015 expects Group net sales to increase overall to between 12.6 billion euros and 12.8 billion euros (previously: 12.3 billion - 12.5 billion euros).EBITDA pre exceptionals are forecast to come in between 3,580 million and 3,650 million euros in FY 2015 (previously: 3,450 million – 3,550 million euros).Earnings per share pre exceptionals are expected to be between 4.80 and 4.95 euros (previously: 4.60 – 4.80 euros).  Full Article

Merck KGaA's Sigma-Aldrich sells some assets to Honeywell
Tuesday, 20 Oct 2015 06:05am EDT 

Merck KGaA:Says Sigma-Aldrich has agreed to sell parts of solvents business to Honeywell.Asset sale includes Sigma-Aldrich’s solvents and inorganics business in Europe.Sale part of commitments Merck has made to receive European Union antitrust approval for $17 billion acquisition of Sigma-Aldrich.Transaction is final step towards winning of EU antitrust approval for acquisition of Sigma-Aldrich.Continues to expect closing of Sigma-Aldrich takeover by end of Nov. 2015.  Full Article

Merck KGaA to operate uniformly as Merck outside US and Canada
Wednesday, 14 Oct 2015 02:53am EDT 

Merck KGaA:Says outside United States and Canada, company will operate uniformly as Merck.With introduction of new brand design, previously independent divisional brands Merck Serono and Merck Millipore will be eliminated.  Full Article

Merck appoints Oschmann as CEO to replace Kley - Reuters
Tuesday, 13 Oct 2015 07:48am EDT 

Merck KGaA:Said it would promote its deputy chief executive, Stefan Oschmann, to the top job in April next year to replace Karl-Ludwig Kley, who will retire - Reuters.Oschmann to take over as chief executive after the group's annual shareholder meeting on April 29, 2016.Kley's current contract would have expired in September 2016.Oschmann, previously the head of its pharma business, became deputy chief executive at the beginning of this year.Before joining Merck KGaA in 2011, German-born Oschmann was in charge of Merck & Co Inc's emerging markets operations.  Full Article

Merck KGaA says avelumab alliance with Pfizer on track - Reuters
Thursday, 1 Oct 2015 09:20am EDT 

Merck KGaA:Says avelumab alliance with Pfizer on track - Reuters.Says it started investigating a novel, potential first-in- class bi-functional immunotherapy in clinical trials.Says working towards at least one additional launch per year in 2017-2022 for avelumab.Says it expects more than 3,000 patients treated with avelumab by 2016.  Full Article

More From Around the Web

BRIEF-Ablynx's partner Merck reports encouraging results with nanobody

* Ablynx's partner, Merck KGaA, reports encouraging results with the bi-specific nanobody anti-il-17a/f (m1095) in a phase ib clinical study in patients with psoriasis